Wedbush Starts Audentes Therapeutics (BOLD) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
Cowen Starts Audentes Therapeutics (BOLD) at Outperform
August 15, 2016 6:56 AM EDTCowen initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating.
For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.
Shares of Audentes Therapeutics closed at $14.70 yesterday.
... More


